

## **Quality Policy of the MSc "Cell and Gene Therapies from bench to bedside and Good Manufacturing Practices"**

The Department of Medicine, in collaboration with the Quality Assurance Unit and the competent authorities of the University of Patras, has harmonized the Quality Policy of the Postgraduate Programme "Cell and Gene Therapies from bench to bedside and Good Manufacturing Practices" with the Quality Policy of the Department and the University of Patras.

### *Vision / Mission of the Department of Medicine*

The education at the Department of Medicine of the University of Patras aims at providing excellent education and training, scientific and ethical, for health care professionals based on the intertemporal Hippocratic view of respect for the patient, who is the final recipient of the quality of medical education. The Department of Medicine of the University of Patras aspires to impart, above all, the ethical values that guide the practice of medicine to the student and to provide him/her with the necessary scientific knowledge to respond to the modern, ever-changing and demanding environment of Medical Science. At the same time, its purpose is to instill an academic mindset and to enable anyone who wishes to do so, to acquire the knowledge needed, in order to enter the field of academic medicine as a researcher and teacher.

The objective of the Interdisciplinary Postgraduate Programme of the Department of Medicine of the University of Patras and the Department of Biomedical Sciences of the University of West Attica, "Cell and Gene Therapies from bench to bedside and Good Manufacturing Practices" is:

-the excellent postgraduate level education and specialization of scientists in cell and gene therapies (CGT), through the provision of high quality expertise in order to enable graduates to be able to adopt and respond to the new challenges posed by the evolution of the science of medicine, through personalised medicine and closed systems in cell and gene therapies, which are already rapidly expanding worldwide. CGTs are now at the forefront of modern personalised medicine and over the last decade have shown great progress in treating multiple diseases that until recently were considered incurable.

The MSc "Cell and Gene Therapies from bench to bedside and Good Manufacturing Practices" is in line with the vision, mission and strategic development plan of the University of Patras, as the strategic goals set in its Quality Policy, since its foundation, are:

☒ The promotion of knowledge and the provision of high quality postgraduate education, through a high level of specialization excellence in the field of Advanced Therapeutic Medicinal Products (ATMPs). Monitoring, Disseminating and Applying cutting-edge technology and scientific developments.

- The implementation of a modern curriculum through a student-centred educational process that is in line with the latest pedagogical developments. Enhancing student-centred learning through ensuring a conducive learning environment and providing educational opportunities equally to all students.
- The provision of high quality interdisciplinary training of biomedical scientists in the fields of pre-clinical research, translational research for the implementation of cell and gene therapies, applicable for the treatment of hitherto incurable diseases, resulting in scientific advancement , meeting health needs and consequently health promoting.
- The provision of quality services to students at academic and administrative level in order to enable their study.
- The strengthening of the link between the MSc "Cell and Gene Therapies" and the labour market, through the promotion of employment of its graduates as executives in the fields of Biotechnology and Health.
- The further development and consolidation of the MSc "Cell and Gene Therapies" at national and international level will be supported.

The quality objectives of the MSc "Cell and Gene Therapies" from bench to bedside and Good Manufacturing Practices" follow the strategic orientation of the University of Patras, which is to provide high quality education, develop cutting-edge scientific fields and strengthen its extroversion and international presence.

These objectives are achieved through the quality assurance procedures as recorded in the University's Internal Quality Assurance System and implemented at the level of the Department with the specificity required in each case. All quality assurance procedures of the Department of Medicine are subject to inspection and review, which is carried out annually by the Internal Evaluation Teams (OMEA) in collaboration with the Quality Assurance Unit (MODIP). The MSc "Cell and Gene Therapies from bench to bedside and Good Manufacturing Practices" in the implementation of its Quality Policy is in close collaboration with the relevant departments of the University and particularly with MODIP, to ensure that it is fully compliant with the guidelines and requirements of the Hellenic Authority for Higher Education (HAHE).